
Senior Director, Payer Accounts
Who We Are:
Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.
The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.
The Role:
- Lead payer team to develop and implement strategies to maximize product access.
- Establish and maintain relationships with key decision makers, including medical and pharmacy directors.
- Negotiate and execute contracts with assigned targeted accounts, help provide access for clinical and/or economic discussions.
- Ability to articulate the value proposition of Cogent’s products to appropriate customers.
- Collaborate and align on pricing & contracting strategies, HEOR evidence generation plans and payer marketing initiatives.
- Work with multiple stakeholders across internal divisions (Sales, Contract & Pricing, Medical, Trade, Legal/Compliance and Marketing) and serve as the main point of contact for account and decision making.
- Formulate, implement, and regularly assess business plan with internal team members to achieve business objectives and utilize all available resources to maximize product & patient access.
- Adhere to relevant regulatory and compliance guidelines and Company policies.
- Attend and participate in meetings and/or conferences as requested by management.
Qualifications:
- Bachelor’s degree required, MBA or other advanced degree preferred.
- 10-12+ years of pharmaceutical industry experience with at least 8 in market access account management and/or leadership.
- Demonstrated success in engaging with US Payers, including PBM’s, state Medicaid agencies etc.
- Strong abilities in communication and presentation skills.
- Skilled in strategic thinking, leadership negotiation and relationship management.
- Ability to travel up to 50%.
Salary Range:
240,000 - 280,000 $USD
Apply for this job
*
indicates a required field